The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary

Abstract

Get full access to this article

View all access options for this article.

References

Río

Nos

Tintoré

. Defining the response to interferon-beta in relapsing–remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344–352.

Río

Rovira

Tintoré

. Relationship between MRI lesion activity and response to IFN-beta in relapsing–remitting multiple sclerosis patients. Mult Scler 2008; 14: 479–484.

Rudick

Lee

Simon

. Defining interferon β response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548–555.

Sormani

Signori

Stromillo

. Refining response to treatment as defined by the Modified Rio Score. Mult Scler 2013; 19: 1246–1247.

Hutchinson

MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary. Mult Scler 2014; 20: 284–285.

Popescu

Agosta

Hulst

. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013; 84: 1082–1091.

Teunissen

Menge

Altintas

. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 2013; 19: 1802–1809.

Teunissen

Tumani

Engelborghs

. Biobanking of CSF: International standardization to optimize biomarker development. Clin Biochem 2014; 47: 288–292.

Gnanapavan

Hegen

Khalil

. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology 2014; 83: 1210–1216.

10.

Rotstein

Healy

Malik

. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 2015; 72: 152–158.